WO2003051912A3 - Proteines purifiees du virus de l'hepatite c utilisables en diagnostic et therapie - Google Patents

Proteines purifiees du virus de l'hepatite c utilisables en diagnostic et therapie Download PDF

Info

Publication number
WO2003051912A3
WO2003051912A3 PCT/EP2002/014480 EP0214480W WO03051912A3 WO 2003051912 A3 WO2003051912 A3 WO 2003051912A3 EP 0214480 W EP0214480 W EP 0214480W WO 03051912 A3 WO03051912 A3 WO 03051912A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
diagnostic
envelope proteins
present
therapeutic use
Prior art date
Application number
PCT/EP2002/014480
Other languages
English (en)
Other versions
WO2003051912A9 (fr
WO2003051912A2 (fr
Inventor
Geert Maertens
Erik Depla
Fons Bosman
Original Assignee
Innogenetics Nv
Geert Maertens
Erik Depla
Fons Bosman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv, Geert Maertens, Erik Depla, Fons Bosman filed Critical Innogenetics Nv
Priority to IL16223602A priority Critical patent/IL162236A0/xx
Priority to KR10-2004-7009720A priority patent/KR20040076869A/ko
Priority to BR0215081-6A priority patent/BR0215081A/pt
Priority to NZ533396A priority patent/NZ533396A/en
Priority to AU2002361160A priority patent/AU2002361160B2/en
Priority to CA002468690A priority patent/CA2468690A1/fr
Priority to EP02796675A priority patent/EP1461080A2/fr
Priority to JP2003552792A priority patent/JP2005516939A/ja
Publication of WO2003051912A2 publication Critical patent/WO2003051912A2/fr
Publication of WO2003051912A3 publication Critical patent/WO2003051912A3/fr
Publication of WO2003051912A9 publication Critical patent/WO2003051912A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé permettant de purifier des protéines d'enveloppe simple ou d'oligomères spécifiques du VHC (virus de l'hépatite C) recombinant. Ces protéines sont choisies dans le groupe constitué des E1 et/ou E2 et/ou E1/E2. La caractéristique du procédé est qu'au moment de la lyse des cellules transformées, pour isoler la protéine exprimée par recombinaison, on utilise un agent de clivage de la liaison bisulfure de façon à réaliser une réduction ou un clivage de la liaison bisulfure. L'invention concerne également, d'une part une composition isolée par un tel procédé, d'autre part l'application diagnostic et thérapeutique de ces compositions, et enfin l'utilisation des peptides et de la protéine E1 du VHC pour établir un pronostic ou pour surveiller l'efficacité clinique et/ou l'avantage clinique du traitement contre le VHC.
PCT/EP2002/014480 2001-12-18 2002-12-18 Proteines purifiees du virus de l'hepatite c utilisables en diagnostic et therapie WO2003051912A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL16223602A IL162236A0 (en) 2001-12-18 2002-12-18 Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
KR10-2004-7009720A KR20040076869A (ko) 2001-12-18 2002-12-18 진단적 및 치료적 용도를 위한 정제된 ｃ형 간염 바이러스외피 단백질
BR0215081-6A BR0215081A (pt) 2001-12-18 2002-12-18 Proteìnas purificadas do envoltório do vìrus de hepatite c para uso diagnóstico e terapêutico
NZ533396A NZ533396A (en) 2001-12-18 2002-12-18 Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002361160A AU2002361160B2 (en) 2001-12-18 2002-12-18 Purified Hepatitis C virus envelope proteins for diagnostic and therapeutic use
CA002468690A CA2468690A1 (fr) 2001-12-18 2002-12-18 Proteines purifiees du virus de l'hepatite c utilisables en diagnostic et therapie
EP02796675A EP1461080A2 (fr) 2001-12-18 2002-12-18 Proteines purifiees du virus de l'hepatite c utilisables en diagnostic et therapie
JP2003552792A JP2005516939A (ja) 2001-12-18 2002-12-18 診断及び治療用途の精製ｃ型肝炎ウイルス外被タンパク質

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2051001A 2001-12-18 2001-12-18
US10/020,510 2001-12-18
US41835802P 2002-10-16 2002-10-16
US60/418,358 2002-10-16

Publications (3)

Publication Number Publication Date
WO2003051912A2 WO2003051912A2 (fr) 2003-06-26
WO2003051912A3 true WO2003051912A3 (fr) 2004-03-04
WO2003051912A9 WO2003051912A9 (fr) 2004-07-15

Family

ID=26693530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/014480 WO2003051912A2 (fr) 2001-12-18 2002-12-18 Proteines purifiees du virus de l'hepatite c utilisables en diagnostic et therapie

Country Status (12)

Country Link
EP (1) EP1461080A2 (fr)
JP (1) JP2005516939A (fr)
KR (1) KR20040076869A (fr)
CN (1) CN1622828A (fr)
AU (1) AU2002361160B2 (fr)
BR (1) BR0215081A (fr)
CA (1) CA2468690A1 (fr)
IL (1) IL162236A0 (fr)
MX (1) MXPA04005891A (fr)
NZ (1) NZ533396A (fr)
RU (1) RU2319505C2 (fr)
WO (1) WO2003051912A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2002085932A2 (fr) 2001-04-24 2002-10-31 Innogenetics N.V. Constructions et methodes relatives a l'expression de proteines d'enveloppe recombinantes du vhc
FR2859221B1 (fr) * 2003-08-28 2005-10-14 Centre Nat Rech Scient Vecteur de co-expression de domaines membranaires de proteines d'enveloppe d'un virus et utilisations
EP1574517A1 (fr) 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 contenant les ponts disulfure spécifiques
EP1809773B1 (fr) * 2004-10-18 2014-07-16 Globeimmune, Inc. Moyens therapeutiques a base de levure contre l'infection par hepatite c chronique
CN100365124C (zh) * 2005-10-27 2008-01-30 云南大学 一段丙型肝炎病毒特异性cDNA序列的应用
WO2009030872A1 (fr) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Matériaux et procédés pour le traitement de l'hépatite c
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
NZ597314A (en) 2009-06-05 2013-07-26 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
EP2507262A1 (fr) 2009-11-30 2012-10-10 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre le virus syncytial respiratoire humain (hrsv) et polypeptides comprenant celles-ci pour la prévention et/ou le traitement d'infections du tractus respiratoire
EP2720716B1 (fr) 2011-06-14 2018-03-21 Globeimmune, Inc. Compositions immunotherapeutiques pour le traitement ou prévention d'une infection par le virus delta de l'hépatite
RU2570553C2 (ru) * 2013-11-20 2015-12-10 Федеральное бюджетное учреждение "Всероссийский научно-исследовательский институт лесоводства и механизации лесного хозяйства (ФБУ ВНИИЛМ) Способ очистки вирусных полиэдров
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
CN107002079A (zh) 2014-09-17 2017-08-01 衣阿华大学研究基金会 作为免疫调节剂和疫苗组分的病毒rna区段
US20190284230A1 (en) * 2016-09-29 2019-09-19 Macfarlane Burnet Institute For Medical Research And Public Health Limited Assembled glycoproteins
WO2020117760A1 (fr) * 2018-12-03 2020-06-11 Duke University Procédé de purification de nanoparticules et de protéines recombinantes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012677A2 (fr) * 1993-11-04 1995-05-11 Innogenetics N.V. Epitopes de lymphocytes t humains immunodominants du virus de l'hepatite c
WO1999067285A1 (fr) * 1998-06-24 1999-12-29 Innogenetics N.V. Particules de proteines d'enveloppe de vhc: utilisation pour la vaccination

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012677A2 (fr) * 1993-11-04 1995-05-11 Innogenetics N.V. Epitopes de lymphocytes t humains immunodominants du virus de l'hepatite c
WO1999067285A1 (fr) * 1998-06-24 1999-12-29 Innogenetics N.V. Particules de proteines d'enveloppe de vhc: utilisation pour la vaccination

Also Published As

Publication number Publication date
CN1622828A (zh) 2005-06-01
KR20040076869A (ko) 2004-09-03
NZ533396A (en) 2005-04-29
AU2002361160B2 (en) 2008-07-03
EP1461080A2 (fr) 2004-09-29
BR0215081A (pt) 2004-10-19
RU2319505C2 (ru) 2008-03-20
WO2003051912A9 (fr) 2004-07-15
JP2005516939A (ja) 2005-06-09
CA2468690A1 (fr) 2003-06-26
MXPA04005891A (es) 2004-09-13
AU2002361160A1 (en) 2003-06-30
WO2003051912A2 (fr) 2003-06-26
IL162236A0 (en) 2005-11-20
RU2004116914A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
WO1996004385A3 (fr) Proteines purifiees d'enveloppe de virus de l'hepatite c a usage diagnostic et therapeutique
WO2003051912A3 (fr) Proteines purifiees du virus de l'hepatite c utilisables en diagnostic et therapie
Usami et al. A 28-kDa protein with disintegrin-like structure (jararhagin-C) purified from Bothrops jararaca venom inhibits collagen-and ADP-induced platelet aggregation
Randolph et al. Amino acid sequence of fibrolase, a direct‐acting fibrinolytic enzyme from agkistrodon contortrix contortrix venom
WO2002086100A3 (fr) Expression, dans la levure, de proteines de l'enveloppe du virus de l'hepatite c (vhc) a nucleo-glycosylation
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
JP2001514858A5 (fr)
WO2004043339A3 (fr) Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
CA2404163A1 (fr) Production de facteurs de coagulation sanguine recombines dans des lignees de cellules humaines
WO1995001442A3 (fr) Sequences de nucleotides et sequences d'acides amines du gene d'enveloppe 1 de 51 isolats du virus de l'hepatite c et utilisation de reactifs derives desdites sequences en tant que reactifs de diagnostic et vaccins
EP0837131A3 (fr) Composé contenant la protéine liant la fibronectine obtenu à partir de Staphylococcus
EP2330127A3 (fr) Protéines de domaine de Kunitz à inhibition de kallicréine et acides nucléiques le codant
JP2004536077A5 (fr)
WO2004085633A8 (fr) Nouveau virus humain provoquant le syndrome respiratoire aigu severe (sars) et son utilisation
WO2004048402A3 (fr) Gene de fusion ns3/4a non structurel a codons optimises du virus de l'hepatite c
Gu et al. Identification of salivary proteins inhibiting herpes simplex virus 1 replication
MXPA05005202A (es) Vacuna.
Proost et al. Chemical synthesis, purification and folding of the human monocyte chemotactic proteins MCP-2 and MCP-3 into biologically active chemokines
WO2005052159A8 (fr) Homologue d'interleukine-10 et ses utilisations
WO2002055548A8 (fr) Proteines d'enveloppe purifiees du virus de l'hepatite c a usage diagnostique et therapeutique
WO2004087062A3 (fr) Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
WO2004014936A3 (fr) Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications.
Holtet et al. Receptor‐binding domain of human α2‐macroglobulin Expression, folding and biochemical characterization of a high‐affinity recombinant derivative
JPH1080281A (ja) 新規蛋白質及びその製造方法
JP2005502327A5 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002361160

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2468690

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 162236

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 533396

Country of ref document: NZ

Ref document number: 1600/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005891

Country of ref document: MX

Ref document number: 2002796675

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003552792

Country of ref document: JP

Ref document number: 1020047009720

Country of ref document: KR

COP Corrected version of pamphlet

Free format text: PAGE 52/69, DRAWINGS, ADDED

WWE Wipo information: entry into national phase

Ref document number: 2004116914

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 20028282027

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002796675

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 533396

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 533396

Country of ref document: NZ